ENLV Enlivex Therapeutics Ltd

  1. Stocks
  2. Healthcare
  3. NASDAQ: ENLV

Price (delayed)

$1.62

Market cap

$30.13M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.56

Enterprise value

$2.81M

enlivex therapeutics ltd., a clinical stage immunotherapy company, engages in developing allogeneic drugs for immune system rebalancing. its product candidate is allocetra, an immunotherapy candidate, which is in phase iib ...

Highlights
Enlivex Therapeutics's EPS has increased by 8% YoY but it has decreased by 6% from the previous quarter
Enlivex Therapeutics's net income has decreased by 7% from the previous quarter but it has increased by 6% YoY
ENLV's equity is down by 47% year-on-year and by 22% since the previous quarter
The company's quick ratio fell by 41% YoY and by 36% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: https://www.enlivex.com/
Peers: OMER OMGA

Key stats

What are the main financial stats of ENLV
Market
Shares outstanding
18.6M
Market cap
$30.13M
Enterprise value
$2.81M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$29.4M
EBITDA
-$28.56M
Free cash flow
-$23.63M
Per share
EPS
-$1.56
Free cash flow per share
-$1.27
Book value per share
$1.62
Revenue per share
$0
TBVPS
$1.98
Balance sheet
Total assets
$36.83M
Total liabilities
$6.75M
Debt
$0
Equity
$30.08M
Working capital
$27.7M
Liquidity
Debt to equity
0
Current ratio
5.57
Quick ratio
4.51
Net debt/EBITDA
0.96
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-59.1%
Return on equity
-71%
Return on invested capital
-90.4%
Return on capital employed
-95.5%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ENLV stock price

How has the Enlivex Therapeutics stock price performed over time
Intraday
0%
1 week
12.5%
1 month
-62.41%
1 year
-42.14%
YTD
-40%
QTD
-57.26%

Financial performance

How have Enlivex Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$29.4M
Net income
-$29.07M
Gross margin
N/A
Net margin
N/A
The company's operating income fell by 14% YoY and by 9% QoQ
Enlivex Therapeutics's net income has decreased by 7% from the previous quarter but it has increased by 6% YoY

Growth

What is Enlivex Therapeutics's growth rate over time

Valuation

What is Enlivex Therapeutics stock price valuation
P/E
N/A
P/B
1
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Enlivex Therapeutics's EPS has increased by 8% YoY but it has decreased by 6% from the previous quarter
ENLV's equity is down by 47% year-on-year and by 22% since the previous quarter
ENLV's P/B is 23% below its 5-year quarterly average of 1.3 and 17% below its last 4 quarters average of 1.2

Efficiency

How efficient is Enlivex Therapeutics business performance
Enlivex Therapeutics's ROE has plunged by 52% YoY and by 25% from the previous quarter
Enlivex Therapeutics's ROA has decreased by 46% YoY and by 24% from the previous quarter
The ROIC has contracted by 42% from the previous quarter but it has grown by 22% YoY

Dividends

What is ENLV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ENLV.

Financial health

How did Enlivex Therapeutics financials performed over time
The total assets has declined by 46% year-on-year and by 22% since the previous quarter
The company's quick ratio fell by 41% YoY and by 36% QoQ
ENLV's debt is 100% lower than its equity
ENLV's equity is down by 47% year-on-year and by 22% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.